Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries.
Publication/Presentation Date
8-1-2009
Abstract
BACKGROUND: Stent thrombosis (ST) is an uncommon but serious complication of drug-eluting and bare metal stents. To assess drug-eluting stent ST in contemporary practice, we analyzed 2-year data from the 7492-patient ARRIVE registry.
METHODS AND RESULTS: Patients were enrolled at the initiation of percutaneous coronary intervention with no inclusion/exclusion criteria beyond use of the paclitaxel-eluting TAXUS stent. Two-year follow-up was 94% with independent adjudication of major cardiac events. A second, autonomous committee adjudicated Academic Research Consortium (ARC) definite/probable ST. Cumulative 2-year ARC-defined ST was 2.6% (1.0% early ST [<30 >days], 0.7% late ST [31 to 365 days], and 0.8% very late ST [>1 year]). Simple-use (single-vessel and single-stent) cases had lower rates than expanded use (broader patient/lesion characteristics, 2-year cumulative: 1.4% versus 3.3%, P28 mm, lesion calcification) and late ST (vessel
CONCLUSIONS: The relative risks of early and late ST differ. Knowledge of ST risk for specific subgroups may guide revascularization options until the completion of randomized trials in these broad populations.
Volume
2
Issue
4
First Page
285
Last Page
293
ISSN
1941-7632
Published In/Presented At
Lasala, J. M., Cox, D. A., Dobies, D., Baran, K., Bachinsky, W. B., Rogers, E. W., Breall, J. A., Lewis, D. H., Song, A., Starzyk, R. M., Mascioli, S. R., Dawkins, K. D., Baim, D. S., & ARRIVE 1 and ARRIVE 2 Participating Physicians (2009). Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circulation. Cardiovascular interventions, 2(4), 285–293. https://doi.org/10.1161/CIRCINTERVENTIONS.109.852178.109.852178
Disciplines
Medicine and Health Sciences
PubMedID
20031730
Department(s)
Department of Medicine
Document Type
Article